# Pizarra — PT-pseudo_575cb2819e96 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_575cb2819e96
Task: 1

Encounter: Urology - outpatient on 24 Jan 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 7.4 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.25 ng/mL²
  - PSA velocity: 0.39 ng/mL/yr
  - Prior PSA: 7.0 ng/mL
  - Prostate volume: 28.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7299785 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes
  - Problem list / PMHx: Type 2 diabetes
  - Current medication: metformin, empagliflozin
  - Allergies: NKA
  - Additional notes: PSA 7.4 ng/mL. PI-RADS 5. PSAD 0.25. Prostate volume 28 mL. csPCa 0.73.

Vitals: weight 58 kg, height 175 cm, BMI 18.9, BP 137/80 mmHg, HR 69 bpm. Smoking: Non-smoker.

Chief complaint: Persistent elevation of prostate-specific antigen levels necessitates clinical reassessment after an earlier Negative biopsy.

History: A 67-year-old retired firefighter initially entered the clinical pathway three years ago after a routine screening flagged an elevated prostate-specific antigen value. He has navigated Type 2 diabetes for more than ten years using metformin and empagliflozin, maintaining recent hemoglobin A1c measurements near 58 mmol/mol. A previous systematic transrectal ultrasound biopsy returned entirely benign tissue. Urinary complaints are minimal, scoring just 1 point on the International Prostate Symptom Score questionnaire. He abstains completely from alcohol and walks for twenty minutes every day. Married and Lives with partner in a ground-floor apartment, he previously opted out of prostate cancer research trials. His surgical background includes a laparoscopic cholecystectomy performed in 2015, alongside occasional mild knee discomfort stemming from his former occupational duties. He remains a Non-smoker. While the recent magnetic resonance imaging results have prompted some concern, he continues to prioritize his daily fitness regimen.

Physical examination: DRE — texture: smooth and symmetric; size: normal; consistency: firm; mobility: unrestricted; asymmetry: none. General inspection reveals a well-nourished individual with a body mass index of 18.9. Blood pressure measures 137/80 mmHg, and the cardiac rhythm remains regular at 69 beats per minute. No abdominal masses or peripheral lymphadenopathy are detectable upon palpation.

Patient info: retired firefighter; Married; Lives with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 1/35 (mild LUTS).


Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.84 +/- 0.13   (95% CI 0.50-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.11  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.07  (few labelled cases resemble this one)
  - 7.8 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=1.0, psa=7.4, age=67.0, psad=0.25, dre_ord=0.0, vol=28.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (0.39 ng/mL/yr) against the prior PSA (7.0 ng/mL) and the current PSA (7.4 ng/mL), which suggests a rapid rise. It also could not incorporate the specific details from the mpMRI report (PI-RADS 5) or the full context of the PSA history/laboratory panel, which are crucial for interpreting the risk stratification beyond the static PI-RADS score.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a high probability of biopsy (0.84). This could be wrong because the prior is blind to the fact that the prior biopsy was negative, which fundamentally changes the interpretation of the current high PSA and PI-RADS 5. Furthermore, the prior does not account for the specific PSA velocity (0.39 ng/mL/yr), which might suggest a different trajectory than the model expects. The wide error bar (0.13) indicates significant disagreement among the 91 cases, suggesting the model is highly sensitive to missing context.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report provides specific features or confidence levels beyond the PI-RADS 5, it could refine the risk assessment.
  <document> PSA history (trend) -> If the trend shows a very rapid rise, it might increase the urgency for intervention.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the clinical suspicion or previous management decisions.
  <document> laboratory panel -> This panel could provide context on other markers that might influence the decision threshold.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.
  
  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_575cb2819e96", "radiology_report": "Maastricht UMC+ | Radiology | 20 January 2025 | mpMRI Prostate\nClinical context: 67-year-old man presenting with PSA 7.4 ng/mL and a previous Negative systematic biopsy.\nFINDINGS:\nProstatic volume registers at 28.0 mL. A discrete abnormality occupies the right posterior mid-gland peripheral zone, spanning 14 x 10 x 12 mm. T2-weighted sequences show pronounced hypointensity against the normal peripheral zone tissue. Diffusion-weighted imaging confirms marked restriction, mirrored by low apparent diffusion coefficient values. Dynamic contrast sequences demonstrate early, focal enhancement within the same region. The transition zone remains clear of significant nodular hyperplasia. There is no evidence of seminal vesicle invasion or extraprostatic extension.\nIMPRESSION:\nPI-RADS 5 lesion in the right posterior mid-gland peripheral zone.\nprostate volume 28.0; PSA density 0.25.\ncsPCa probability 0.7299785."}
  
  **psa_trend**
  {"case_id": "PT-pseudo_575cb2819e96", "psa_trend": [{"date": "Sep 2023", "val": 5.8}, {"date": "Feb 2024", "val": 7.2}, {"date": "Aug 2024", "val": 4.0}, {"date": "Jan 2025", "val": 7.4}]}
  
  **previous_notes**
  {"case_id": "PT-pseudo_575cb2819e96", "previous_notes": [{"date": "30 Jan 2024", "author": "Dr. N. Kuiper (GP)", "text": "Clinical review focused on a sustained rise in prostate-specific antigen values. An earlier measurement from September 2023 recorded 6.2 ng/mL, indicating a gradual upward trajectory. The preceding systematic biopsy yielded Negative results for malignancy. Current pharmacotherapy includes metformin and empagliflozin to manage Type 2 diabetes, with glycaemic parameters remaining stable. Recorded for specialist urological follow-up."}, {"date": "03 Aug 2023", "author": "Dr. N. Kuiper (GP)", "text": "Annual wellness assessment conducted when the patient was 66 years old. Cardiovascular metrics showed a blood pressure reading of 138/82 mmHg. Type 2 diabetes was addressed through dietary adjustments and metformin administration. A general health screening captured a prostate-specific antigen level of 5.8 ng/mL. The individual reported no lower urinary tract complaints at the time."}]}
  
  **laboratory_results**
  {"case_id": "PT-pseudo_575cb2819e96", "laboratory_results": [{"name": "PSA", "val": "7.4 ng/mL", "date": "26 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.83 ng/mL", "date": "26 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "11%", "date": "26 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "15.7 g/dL", "date": "26 Dec 2024", "flag": ""}, {"name": "WBC", "val": "8.3 x10^9/L", "date": "26 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "261 x10^9/L", "date": "26 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "86 umol/L", "date": "26 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "26 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "13.4 nmol/L", "date": "26 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "86 U/L", "date": "26 Dec 2024", "flag": ""}, {"name": "LDH", "val": "148 U/L", "date": "26 Dec 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Do NOT call this. In this reading form the family-history anamnesis is not part of the biopsy work-up, and a positive or negative first-degree history does not change whether this patient is sampled today.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - mpMRI report: PI-RADS 5 lesion in the right posterior mid-gland peripheral zone.
  - PSA trend: Rapid rise from 4.0 ng/mL (Aug 2024) to 7.4 ng/mL (Jan 2025).
  - Previous notes: Prior biopsy was Negative, suggesting the current elevation warrants re-evaluation.
  - Laboratory results: PSA is 7.4 ng/mL, and %Free PSA is 11%.
  
  AGAINST sampling this patient now:
  - Previous notes: Prior biopsy was Negative.
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
  The evidence strongly points toward sampling due to the high-risk PI-RADS 5 finding and the concerning PSA velocity, which contradicts the negative prior biopsy. This leans toward the statistical prior but with stronger clinical justification based on imaging and trend data.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the patient has a high-risk PI-RADS 5 lesion and a concerning PSA velocity of 0.39 ng/mL/yr, which contradicts the prior negative biopsy. The decision is driven by the PI-RADS 5 finding and the rapid PSA rise from 4.0 ng/mL to 7.4 ng/mL over the last year. The statistical prior suggested biopsy, which is strongly supported by the specific imaging and trend data.

Variables that carried weight: bx=decisive, age=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
